The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope

This guideline will provide up-to-date, evidence-based recommendations on the safe use of non-biologic DMARDs, also called conventional synthetic DMARDs (csDMARD), across the full spectrum of autoimmune rheumatic diseases. The guideline will update the guideline published in 2017 and will be expanded to include people of all ages. Updated information on the monitoring of DMARDs and vaccinations will be included. The guideline will be developed using the methods and processes described in the British Society for Rheumatology's 'Creating clinical guidelines: our protocol', updated 2023.

Citation

Mercer, L., Abhishek, A., Kavirayani, A., Ahmed, A., Davidson, A., Foulkes, A., Jones, C., Nash, C., Rose-Parfitt, E., Dhillon, E., Zabate, G., Twohig, H., De Vere, H., Scott, J., Reynolds, J., Holmes, J., Hartley, K., Warrier, K., Nowak, K., Parsons, K., … Galloway, J. (2024). The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope. Rheumatology advances in practice, 8(3), rkae077. https://doi.org/10.1093/rap/rkae077

DOI

10.1093/rap/rkae077

URI

https://hdl.handle.net/20.500.14709/296

Usage rights

CC BY-NC 4.0

License

https://creativecommons.org/licenses/by-nc/4.0/